Shots:

• RemeGen to receive $200M up front for development and commercialization rights of disitamab vedotin outside of Remegen’s territory & ~$2.4B upon the achievement of milestones across multiple indications along with royalties on sales of the therapy in Seagen’s territory
• RemeGen will retain development & commercialization rights of the therapy in Asia (Ex-Japan & Singapore). Seagen will be responsible for global development whereas RemeGen will fund and operationalize the portion of clinical trials & lead clinical development and regulatory submissions specific to its territory
• The collaboration leverages companies' expertise in developing ADCs along with Seagen’s development capabilities

Ref: Businesswire | Image: Businesswire